Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards the overcoming of anticancer drug resistance mediated by p53 mutations.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Mar 2020

Cao Xin, Hou Jiayun, An Quanlin, Assaraf Yehuda G, Wang Xiangdong

Abstract excerpt

Cancer continues to be a leading threat to human health and life. Resistance to anti-cancer drugs is a major impediment towards efficacious cancer treatment. p53 mutations play an important role in cancer cell resistance to chemotherapeutic drugs. The frequency of p53-based chemoresistance is highly associated with the chemical properties of the anticancer drug, the cellular drug target, the biological function...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Research and Treatments

Share to Drug Development

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 31841768
DOI: 10.1016/j.drup.2019.100671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards the overcoming of anticancer drug resistance mediated by p53 mutations.PMID 31841768Read ↗

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.Semantic proximity Read ↗

Cancer drug resistance: an evolving paradigm.Semantic proximity Read ↗

Drug resistance mechanisms in cancers: Execution of pro-survival strategiesSemantic proximity Read ↗

MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome.Semantic proximity Read ↗

An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.Semantic proximity Read ↗

p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells.Semantic proximity Read ↗

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and OpportunitiesSemantic proximity Read ↗

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor ProgressionSemantic proximity Read ↗

Drug resistance in human cancers - Mechanisms and implications.Semantic proximity Read ↗

Role of p53 in drug resistance in ovarian cancer.Semantic proximity Read ↗

Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?Semantic proximity Read ↗

The Different Mechanisms of Cancer Drug Resistance: A Brief ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.